Department of Biological and Chemical Engineering, Hongik University, Sejong, 30016, Republic of Korea.
BioMAX/N-Bio Institute, Seoul National University, Seoul, 08826, Republic of Korea.
Biotechnol Lett. 2023 Jun;45(5-6):589-600. doi: 10.1007/s10529-023-03364-0. Epub 2023 Mar 27.
S100A8 is highly expressed in several inflammatory and oncological conditions. To address the current lack of a reliable and sensitive detection method for S100A8, we generated a monoclonal antibody with a high binding affinity to human S100A8 to enable early disease diagnosis.
A soluble recombinant S100A8 protein with a high yield and purity was produced using Escherichia coli. Next, mice were immunized with recombinant S100A8 to obtain anti-human S100A8 monoclonal antibodies using hybridoma technology. Lastly, the high binding activity of the antibody was confirmed and its sequence was identified.
This method, including the production of antigens and antibodies, will be useful for the generation of hybridoma cell lines that produce anti-S100A8 monoclonal antibodies. Moreover, the sequence information of the antibody can be used to develop a recombinant antibody for use in various research and clinical applications.
S100A8 在几种炎症和肿瘤条件下高度表达。为了解决目前缺乏可靠和敏感的 S100A8 检测方法的问题，我们生成了一种对人 S100A8 具有高结合亲和力的单克隆抗体，以实现早期疾病诊断。
使用大肠杆菌生产了具有高产量和高纯度的可溶性重组 S100A8 蛋白。接下来，用重组 S100A8 免疫小鼠，使用杂交瘤技术获得抗人 S100A8 单克隆抗体。最后，确认了抗体的高结合活性，并鉴定了其序列。
这种包括抗原和抗体生产的方法将有助于产生产生抗 S100A8 单克隆抗体的杂交瘤细胞系。此外，抗体的序列信息可用于开发用于各种研究和临床应用的重组抗体。
